Danaher

Danaher Corp's CEO Rainer Blair Presents at JPMorgan Healthcare Conference

Danaher's Q4 Update and Synthetic Biology Ambitions: A Catalyst for Growth

丹纳赫

Danaher's 15-minute chart signals MACD Death Cross, narrowing Bollinger Bands.

Danaher's 15-minute chart shows RSI overbought and KDJ death cross.

Danaher Corporation: Analyst Raises Target to $265 from $255

Catalyst<ul> <li>Most analysts rate DHR Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant (3 bearish vs 0 bullish).</li> <li>The technical side is weak, and it is suggested to avoid it.</li></ul>

Key Factors

Danaher reported Q3 non-GAAP adjusted diluted EPS of $1.89, exceeding expectations and attributed to strong execution and bioprocessing performance.Danaher announced a new synthetic biology collaboration with Ansa Biotechnologies to expand access to longer DNA constructs.Danaher insiders sold $235 million worth of stock in the last three months, raising investor scrutiny.

DHR News